News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
9,025 Results
Type
Article (1497)
Company Profile (5)
Press Release (7522)
Section
Business (3614)
Career Advice (10)
Deals (505)
Drug Delivery (5)
Drug Development (1699)
Employer Resources (5)
FDA (297)
Job Trends (301)
News (6033)
Policy (557)
Tag
Academia (20)
Accelerated approval (3)
Adcomms (5)
Allergies (2)
Alliances (1028)
ALS (2)
Alzheimer's disease (16)
Antibody-drug conjugate (ADC) (16)
Approvals (276)
Artificial intelligence (12)
Autoimmune disease (11)
Bankruptcy (5)
Best Places to Work (153)
BIOSECURE Act (1)
Biotechnology (2)
Breast cancer (4)
Cancer (93)
Cardiovascular disease (14)
Career advice (12)
CAR-T (1)
CDC (10)
Cell therapy (8)
Clinical research (1421)
Collaboration (44)
Company closure (2)
Compensation (4)
Complete response letters (4)
COVID-19 (120)
CRISPR (3)
C-suite (36)
Data (62)
Denatured (3)
Depression (2)
Diabetes (1)
Diagnostics (26)
Diversity, equity & inclusion (2)
Drug discovery (4)
Drug pricing (13)
Duchenne muscular dystrophy (4)
Earnings (1062)
Editorial (8)
Employer branding (2)
Employer resources (5)
Events (746)
Executive appointments (36)
FDA (314)
Frontotemporal dementia (2)
Funding (25)
Gene editing (5)
Gene therapy (10)
GLP-1 (19)
Government (93)
Guidances (2)
Healthcare (187)
HIV (12)
Huntington's disease (1)
Immunology and inflammation (28)
Immuno-oncology (4)
Indications (2)
Infectious disease (177)
Inflammatory bowel disease (2)
Inflation Reduction Act (2)
Influenza (4)
Intellectual property (3)
IPO (131)
IRA (3)
Job creations (147)
Job search strategy (9)
JPM (7)
Labor market (4)
Layoffs (29)
Leadership (3)
Legal (153)
Liver cancer (2)
Longevity (1)
Lung cancer (14)
Lymphoma (2)
Machine learning (1)
Management (2)
Manufacturing (13)
MASH (7)
Medical device (16)
Medtech (17)
Mergers & acquisitions (379)
Metabolic disorders (22)
Multiple sclerosis (1)
Neurodegenerative disease (15)
Neuropsychiatric disorders (4)
Neuroscience (38)
Neurotech (1)
NextGen: Class of 2026 (77)
Non-profit (31)
Obesity (13)
Opinion (13)
Ovarian cancer (6)
Pain (1)
Pancreatic cancer (9)
Parkinson's disease (1)
Partnered (1)
Patents (12)
Patient recruitment (1)
People (1365)
Pharmaceutical (2)
Pharmacy benefit managers (1)
Phase 1 (359)
Phase 2 (572)
Phase 3 (582)
Pipeline (96)
Policy (27)
Postmarket research (97)
Preclinical (109)
Prostate cancer (4)
Psychedelics (2)
Radiopharmaceuticals (4)
Rare diseases (22)
Real estate (76)
Recruiting (1)
Regulatory (419)
Reports (2)
Research institute (29)
Resumes & cover letters (1)
RNA editing (2)
RSV (30)
Schizophrenia (1)
Series A (4)
Series B (1)
Sickle cell disease (4)
Special edition (5)
Spinal muscular atrophy (11)
Sponsored (1)
Startups (108)
Stomach cancer (4)
Supply chain (2)
Tariffs (5)
The Weekly (12)
Vaccines (112)
Venture capital (13)
Weight loss (9)
Date
Last 7 days (14)
Last 30 days (46)
Last 365 days (462)
2026 (58)
2025 (463)
2024 (497)
2023 (532)
2022 (727)
2021 (607)
2020 (516)
2019 (409)
2018 (331)
2017 (401)
2016 (429)
2015 (658)
2014 (462)
2013 (384)
2012 (337)
2011 (394)
2010 (385)
Location
Africa (36)
Asia (582)
Australia (171)
California (114)
Canada (38)
China (24)
Colorado (1)
Connecticut (2)
Europe (3179)
Florida (8)
Georgia (4)
Illinois (24)
Indiana (3)
Japan (3)
Maryland (6)
Massachusetts (121)
New Hampshire (4)
New Jersey (41)
New York (12)
North Carolina (9)
Northern California (49)
Oklahoma (1)
Pennsylvania (30)
South America (22)
Southern California (44)
Texas (41)
United States (395)
Utah (3)
Virginia (1)
Washington D.C. (3)
Washington State (7)
Wisconsin (1)
9,025 Results for "gsk".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
GSK Says No to GLP-1s, Prioritizes ‘Downstream Effects’ of Obesity
Instead of joining the increasingly crowded GLP-1 arena, GSK will focus its efforts downstream of obesity—a push currently anchored by its Phase III-ready FGF21 analog efimosfermin alfa for liver fibrosis.
February 4, 2026
·
2 min read
·
Tristan Manalac
Rare diseases
GSK Hands RNA Editor Back to Wave After Underwhelming Early AATD Data
While GSK did not provide a specific reason for returning Wave Life Sciences’ WVE-006, the decision comes after the asset in September 2025 came below analyst expectations in a Phase Ib/IIa AATD study.
February 2, 2026
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
GSK Picks Up RAPT for $2.2B as Miels Makes First Move as CEO
The star of the acquisition, anti-IgE antibody ozureprubart, is being tested as a prophylactic treatment for food allergies, potentially setting up a competition for GSK with Roche’s Xolair.
January 20, 2026
·
2 min read
·
Tristan Manalac
Infectious disease
GSK, Ionis Achieve Functional Cure in Hepatitis B Studies, Clearing Path for FDA Run
Though specific data for bepirovirsen remain under wraps, GSK plans to file for approval in the first quarter of 2026.
January 7, 2026
·
2 min read
·
Tristan Manalac
Collaboration
GSK Joins Growing PD-1 SubQ Push With Alteogen Alliance Worth up to $285M+
Ahead of GSK are Bristol Myers Squibb and Merck, which have already won FDA approvals for subcutaneous formulations of their respective PD-1 blockers Opdivo and Keytruda.
January 21, 2026
·
1 min read
·
Tristan Manalac
Cancer
GSK Cuts Five-Year-Old Cancer Collaboration With Ideaya
GSK and Ideaya first linked up in 2020 to advance novel therapies for solid tumors. It is unclear why the pharma terminated the partnership.
December 8, 2025
·
2 min read
·
Tristan Manalac
Legal
UPDATE: GSK’s Tesaro Sues AnaptysBio Over Current Jemperli Contract; Anaptys Countersues
After GSK subsidiary Tesaro filed a lawsuit Thursday claiming that AnaptysBio breached “certain requirements” under their 2014 license agreement involving GSK’s Jemperli, Anaptys responded Friday morning.
November 21, 2025
·
3 min read
·
Tristan Manalac
Approvals
GSK’s Blenrep Makes Comeback With FDA Nod for Third-Line Multiple Myeloma
The antibody-drug conjugate, withdrawn from the market by GSK in 2022 after failing a confirmatory study, was approved Thursday by the FDA for previously treated patients with multiple myeloma. This is despite a negative advisory committee vote in July.
October 24, 2025
·
2 min read
·
Tristan Manalac
C-suite
GSK’s Emma Walmsley, Pharma’s First Woman CEO, Steps Down After 9 Years
Chief Commerical Officer Luke Miels will replace outgoing GSK CEO Emma Walmsley at the U.K. pharma next year.
September 29, 2025
·
4 min read
·
Annalee Armstrong
Earnings
GSK Points to ‘Macro Factors’ To Explain US Shingrix Demand Crash
Shingrix sales in the U.S. took a 15% dive in the third quarter. GSK is now the second Big Pharma to report declining vaccine sales, after
Sanofi reported
a similar decline last week.
October 29, 2025
·
2 min read
·
Tristan Manalac
1 of 903
Next
